Want to see GB:HEMO full AI Analyst Report?

HemoGenyx Pharmaceuticals Plc (HEMO) Price & Analysis

37 Followers

HEMO Stock Chart & Stats

568.00 p

-12.50 p(-3.23%)

At close: Jan 09 4:00 PM EST

568.00 p

-12.50 p(-3.23%)

Day’s Range― - ―

52-Week Range124.00 p - 1,800.00 p

Previous CloseN/A

Volume114.00

Average Volume (3M)113.41K

Market Cap

£51.27M

Enterprise Value53.32M

Total Cash (Recent Filing)£1.59M

Total Debt (Recent Filing)£2.00M

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Sep 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.21

Shares Outstanding6,799,961

10 Day Avg. Volume30,447

30 Day Avg. Volume113,406

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)21.26

Price to Sales (P/S)0.00

P/FCF Ratio-7.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Therapeutic NicheA clear, specialized focus in hematology/oncology and stem-cell transplantation gives HemoGenyx durable strategic clarity. Niche expertise can support targeted R&D, higher clinical relevance, partner interest, and differentiated pipelines versus broad biotech peers, aiding long-term development alignment.

Debt Reduction TrendObserved reduction in total debt from 2023 to 2025 lowers financing fragility and modestly extends runway for a loss-making biotech. Persistent deleveraging demonstrates management priority on reducing leverage, improving long-term funding optionality and reducing near-term refinancing pressure.

Improving Operating Cash BurnA year-over-year reduction in operating cash burn signals stronger cost control or program prioritization, which can materially extend runway for a pre-revenue biotech. If sustained, lower burn improves ability to reach clinical milestones before needing additional dilutive capital.

Bears Say

Pre-revenue ProfileThe company remains pre-revenue with no product sales, creating structural reliance on external financing or partnerships. Without recurring revenue, long-term viability depends on successful R&D outcomes or deals; this amplifies dilution and execution risk over multiple funding cycles.

Widening Net LossesSubstantially larger net losses year-over-year accelerate depletion of cash and equity, increasing the likelihood of near-term funding needs. Growing losses complicate planning, raise dilution risk, and can force concessions in partnerships or financing terms, undermining strategic flexibility.

Elevated Leverage And Shrinking EquityDebt greater than equity and a materially shrunken equity base reduce the balance sheet cushion for a loss-making company. High leverage restricts financing options, raises bankruptcy risk in stress scenarios, and weakens bargaining power with partners and lenders over the medium term.

HemoGenyx Pharmaceuticals Plc News

Hemogenyx Wins Full Shareholder Backing at AGM, Secures New Capital Flexibility

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) just unveiled an announcement. Hemogenyx Pharmaceuticals reported that shareholders approved all resolutions...

15h ago

Hemogenyx Sends 2025 Annual Report and Sets June AGM

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has provided an announcement. Hemogenyx Pharmaceuticals has dispatched its Annual Report and...

27d ago

Hemogenyx reshapes incentives with new options and extended investor warrants

An update from HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) is now available. Hemogenyx Pharmaceuticals has granted a total...

1M ago

Hemogenyx advances lead CAR-T trial and secures funding to complete Phase 1

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) just unveiled an update. Hemogenyx Pharmaceuticals reported its final audited results for...

2M ago

Hemogenyx Raises £3m to Accelerate HG-CT-1 Trials and Early Commercialisation

The latest announcement is out from HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ). Hemogenyx Pharmaceuticals has raised £3 million...

2M ago

Hemogenyx Files Annual FDA IND Report as AML CAR‑T Trial Shows Early Promise

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has provided an update. Hemogenyx Pharmaceuticals has filed its annual Investigational New...

3M ago

Hemogenyx Advances HG-CT-1 CAR-T Program With Manufacturing Transfer and Trial Expansion

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has issued an announcement. Hemogenyx Pharmaceuticals has completed the technology transfer of...

3M ago

Hemogenyx Pharmaceuticals Updates Share Capital and Voting Rights Structure

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has provided an announcement. Hemogenyx Pharmaceuticals plc, a clinical-stage biopharmaceutical group listed...

4M ago

Hemogenyx Raises £118,632 Through Warrant Exercise and Expands Share Capital

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has shared an update. Hemogenyx Pharmaceuticals has received notices to exercise warrants...

4M ago

Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has provided an announcement. Hemogenyx Pharmaceuticals has raised £2.5 million from a...

5M ago

HEMO FAQ

What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?

HemoGenyx Pharmaceuticals Plc lowest share price was 124.00 p and its highest was 1800.00 p in the past 12 months.

What is HemoGenyx Pharmaceuticals Plc’s market cap?

HemoGenyx Pharmaceuticals Plc’s market cap is £51.27M.

When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?

HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 24, 2026 which is in 85 days.

How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?

HemoGenyx Pharmaceuticals Plc released its earnings results on Apr 30, 2026. The company reported -0.787 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.787 p.

Is HemoGenyx Pharmaceuticals Plc overvalued?

According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does HemoGenyx Pharmaceuticals Plc pay dividends?

HemoGenyx Pharmaceuticals Plc does not currently pay dividends.

What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?

HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?

HemoGenyx Pharmaceuticals Plc has 6,799,961 shares outstanding.

What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?

HemoGenyx Pharmaceuticals Plc reported an EPS of -0.787 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.735%.

Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?

Currently, no hedge funds are holding shares in GB:HEMO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

HemoGenyx Pharmaceuticals Plc Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

-2807.75%

Trailing 12-Months

Asset Growth

-0.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.